The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This study is an randomized double-blind placebo-controlled study to evaluate the efficacy and the safety of oral KHK4577 for 6 weeks in patients with atopic dermatitis. Pharmacokinetics of KHK4577 will also be assessed.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
20 Years to 64 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Subject has signed voluntarily the written informed consent form to participate in this study.
Subject has been diagnosed as atopic dermatitis according to Guidelines for Management of Atopic Dermatitis (2009).
Rajka & Langeland criteria of >/= 4.5 at screening visit
Investigator's Global Assessment (IGA) score of >/= 3 at screening visit
Evidence of skin disorders/conditions that would interfere with the assessment of the effect of the study drug.
Subject received photochemotherapy or systemic immunosuppressants within 2 weeks prior to informed consent.
Subject has any active infectious disease(except localized infection) which needs to treat with systemic antibiotics(eg. antibacterial, antifungal or antiviral drugs) within 4 weeks prior to informed consent.
Subject has complications / history of drug abuse or alcoholism.
Subject has drug allergy or history of allergic reaction to a drug medicine.
Subject has a significant concurrent medical conditions as defined in the study protocol.
Subject is breast-feeding, pregnant or planning to become pregnant in this study period.